Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.
Goswami M, Gui G, Dillon LW, Lindblad KE, Thompson J, Valdez J, Kim DY, Ghannam JY, Oetjen KA, Destefano CB, Smith DM, Tekleab H, Li Y, Dagur P, Hughes T, Marté JL, Del Rivero J, Klubo-Gwiezdzinksa J, Gulley JL, Calvo KR, Lai C, Hourigan CS. Goswami M, et al. Among authors: hourigan cs. J Immunother Cancer. 2022 Jan;10(1):e003392. doi: 10.1136/jitc-2021-003392. J Immunother Cancer. 2022. PMID: 35017151 Free PMC article.
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Stahl M, et al. Among authors: hourigan cs. Blood Rev. 2023 Nov;62:101128. doi: 10.1016/j.blre.2023.101128. Epub 2023 Aug 19. Blood Rev. 2023. PMID: 37704469 Review.
Minimal residual disease in acute myeloid leukaemia.
Hourigan CS, Karp JE. Hourigan CS, et al. Nat Rev Clin Oncol. 2013 Aug;10(8):460-71. doi: 10.1038/nrclinonc.2013.100. Epub 2013 Jun 25. Nat Rev Clin Oncol. 2013. PMID: 23799371 Free PMC article. Review.
Personalized therapy for acute myeloid leukemia.
Hourigan CS, Karp JE. Hourigan CS, et al. Cancer Discov. 2013 Dec;3(12):1336-8. doi: 10.1158/2159-8290.CD-13-0832. Cancer Discov. 2013. PMID: 24327695 Free PMC article.
Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.
Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS. Goswami M, et al. Among authors: hourigan cs. Leukemia. 2014 May;28(5):1167-70. doi: 10.1038/leu.2014.14. Epub 2014 Jan 10. Leukemia. 2014. PMID: 24472813 Free PMC article. No abstract available.
A multigene array for measurable residual disease detection in AML patients undergoing SCT.
Goswami M, McGowan KS, Lu K, Jain N, Candia J, Hensel NF, Tang J, Calvo KR, Battiwalla M, Barrett AJ, Hourigan CS. Goswami M, et al. Among authors: hourigan cs. Bone Marrow Transplant. 2015 May;50(5):642-51. doi: 10.1038/bmt.2014.326. Epub 2015 Feb 9. Bone Marrow Transplant. 2015. PMID: 25665046 Free PMC article. Clinical Trial.
Acute Myeloid Leukemia: Introduction.
Hourigan CS. Hourigan CS. Semin Hematol. 2015 Jul;52(3):149. doi: 10.1053/j.seminhematol.2015.04.004. Epub 2015 Apr 7. Semin Hematol. 2015. PMID: 26111461 No abstract available.
136 results